Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells

Oncogenic receptor tyrosine kinases including anaplastic lymphoma kinase (ALK) are implicated in numerous solid and hematologic cancers. ALK mutations are reported in an estimated 9% of neuroblastoma and recent reports indicate that the percentage of ALK-positive cases increases in the relapsed pati...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Front Oncol
Päätekijät: Alam, Muhammad Wasi, Borenäs, Marcus, Lind, Dan E., Cervantes-Madrid, Diana, Umapathy, Ganesh, Palmer, Ruth H., Hallberg, Bengt
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Frontiers Media S.A. 2019
Aiheet:
Oncology
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6625372/
https://ncbi.nlm.nih.gov/pubmed/31334113
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00579
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia